{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:21:24Z","timestamp":1790173284940,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvsvenous.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular Surgery: Venous and Lymphatic Disorders"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jvsv.2025.102258","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T21:00:07Z","timestamp":1746738007000},"page":"102258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["The role of venoactive compounds in the treatment of chronic venous disease"],"prefix":"10.1016","volume":"13","author":[{"given":"Monika Lecomte","family":"Gloviczki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros K.","family":"Kakkos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Urbanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Chuback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Nicolaides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jvsv.2025.102258_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12325-019-0881-7","article-title":"The Seriousness of chronic venous disease: a review of real-world evidence","volume":"36","author":"Davies","year":"2019","journal-title":"Adv Ther"},{"issue":"1 Suppl","key":"10.1016\/j.jvsv.2025.102258_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/0268355516628359","article-title":"Predicted burden of venous disease","volume":"31","author":"Onida","year":"2016","journal-title":"Phlebology"},{"key":"10.1016\/j.jvsv.2025.102258_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/1358863X211028298","article-title":"An estimate of the economic burden of venous leg ulcers associated with deep venous disease","volume":"27","author":"Kolluri","year":"2022","journal-title":"Vasc Med"},{"issue":"1 Suppl","key":"10.1016\/j.jvsv.2025.102258_bib4","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/0268355514568847","article-title":"Progression in venous pathology","volume":"30","author":"Pannier","year":"2015","journal-title":"Phlebology"},{"key":"10.1016\/j.jvsv.2025.102258_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.avsg.2014.10.009","article-title":"Biomolecular mechanisms in varicose veins development","volume":"29","author":"Segiet","year":"2015","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.jvsv.2025.102258_bib6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMra055289","article-title":"Chronic venous disease","volume":"355","author":"Bergan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvsv.2025.102258_bib7","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1056\/NEJMcp2310224","article-title":"Nonsurgical management of chronic venous insufficiency","volume":"391","author":"Fukaya","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvsv.2025.102258_bib8","first-page":"212","article-title":"Pathophysiology of chronic venous disease","volume":"33","author":"Raffetto","year":"2014","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2025.102258_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jvs.2007.03.052","article-title":"Risk factors for chronic venous disease: the San Diego Population Study","volume":"46","author":"Criqui","year":"2007","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jvsv.2025.102258_bib10","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1161\/CIRCULATIONAHA.118.035584","article-title":"Clinical and genetic determinants of varicose veins","volume":"138","author":"Fukaya","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jvsv.2025.102258_bib11","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1161\/CIRCRESAHA.121.318322","article-title":"Epidemiology and genetics of venous thromboembolism and chronic venous disease","volume":"128","author":"Baylis","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.jvsv.2025.102258_bib12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jvsv.2019.12.075","article-title":"The 2020 update of the CEAP classification system and reporting standards","volume":"8","author":"Lurie","year":"2020","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"10.1016\/j.jvsv.2025.102258_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1258\/phleb.2008.008018","article-title":"Venous clinical severity score and quality-of-life assessment tools: application to vein practice","volume":"23","author":"Vasquez","year":"2008","journal-title":"Phlebology"},{"key":"10.1016\/j.jvsv.2025.102258_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.23736\/S0392-9590.18.03999-8","article-title":"Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I","volume":"37","author":"Nicolaides","year":"2018","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2025.102258_bib15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejvs.2021.12.024","article-title":"Editor's choice - European Society for Vascular Surgery (ESVS) 2022 clinical practice guidelines on the management of chronic venous disease of the lower limbs","volume":"63","author":"De Maeseneer","year":"2022","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jvsv.2025.102258_bib16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jvsv.2022.09.004","volume":"11","author":"Gloviczki","year":"2023","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"10.1016\/j.jvsv.2025.102258_bib17","doi-asserted-by":"crossref","DOI":"10.1201\/9781003328971","volume":"12","author":"Gloviczki","year":"2024","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"Suppl 1","key":"10.1016\/j.jvsv.2025.102258_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12325-020-01219-y","article-title":"The most severe stage of chronic venous disease: an update on the management of patients with venous leg ulcers","volume":"37","author":"Nicolaides","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.jvsv.2025.102258_bib19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/02683555211015020","article-title":"Systematic literature review and network meta-analysis of sulodexide and other drugs in chronic venous disease","volume":"36","author":"Pompilio","year":"2021","journal-title":"Phlebology"},{"key":"10.1016\/j.jvsv.2025.102258_bib20","author":"Perrin"},{"key":"10.1016\/j.jvsv.2025.102258_bib21","first-page":"309","article-title":"Veno-active drugs in the management of chronic venous disease. An international consensus statement: current medical position, prospective views and final resolution","volume":"33","author":"Ramelet","year":"2005","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.jvsv.2025.102258_bib22","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.bcp.2019.04.021","article-title":"Sulodexide promotes arterial relaxation via endothelium-dependent nitric oxide-mediated pathway","volume":"166","author":"Raffetto","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jvsv.2025.102258_bib23","first-page":"1","article-title":"Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence","volume":"27","author":"Nicolaides","year":"2008","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2025.102258_bib24","first-page":"87","article-title":"Management of chronic venous disorders of the lower limbs - guidelines according to scientific evidence","volume":"33","author":"Nicolaides","year":"2014","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2025.102258_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.mvr.2021.104274","article-title":"Lymphotonic activity of Ruscus extract, hesperidin methyl chalcone and vitamin C in human lymphatic smooth muscle cells","volume":"139","author":"Monjotin","year":"2022","journal-title":"Microvasc Res"},{"key":"10.1016\/j.jvsv.2025.102258_bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/jth.14324","article-title":"Sulodexide in venous disease","volume":"17","author":"Carroll","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jvsv.2025.102258_bib27","first-page":"374","article-title":"Venous symptoms: the SYM vein consensus statement developed under the auspices of the European Venous Forum","volume":"35","author":"Perrin","year":"2016","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2025.102258_bib28","doi-asserted-by":"crossref","first-page":"175","DOI":"10.23736\/S0392-9590.20.04388-6","article-title":"Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part II","volume":"39","author":"Nicolaides","year":"2020","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2025.102258_bib29","first-page":"CD003229","article-title":"Phlebotonics for venous insufficiency","volume":"4","author":"Martinez-Zapata","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jvsv.2025.102258_bib30","first-page":"CD003229","article-title":"Phlebotonics for venous insufficiency","volume":"11","author":"Martinez-Zapata","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"4 Suppl","key":"10.1016\/j.jvsv.2025.102258_bib31","first-page":"61","article-title":"Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form","volume":"8","author":"Cospite","year":"1989","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2025.102258_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/jcpt.12247","article-title":"A systematic review of the efficacy and tolerability of hydroxyethylrutosides for improvement of the signs and symptoms of chronic venous insufficiency","volume":"40","author":"Aziz","year":"2015","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.jvsv.2025.102258_bib33","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ejvs.2010.12.003","article-title":"Efficacy and tolerability of a red-vine-leaf extract in patients suffering from chronic venous insufficiency--results of a double-blind placebo-controlled study","volume":"41","author":"Rabe","year":"2011","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jvsv.2025.102258_bib34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.23736\/S0392-9590.17.03815-9","article-title":"Efficacy of Ruscus extract, HMC and vitamin C, constituents of Cyclo 3 fort(R), on improving individual venous symptoms and edema: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials","volume":"36","author":"Kakkos","year":"2017","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2025.102258_bib35","first-page":"CD003230","article-title":"Horse chestnut seed extract for chronic venous insufficiency","volume":"11","author":"Pittler","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jvsv.2025.102258_bib36","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s12325-020-01232-1","article-title":"Sulodexide for the symptoms and signs of chronic venous disease: a systematic review and meta-analysis","volume":"37","author":"Bignamini","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.jvsv.2025.102258_bib37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/000331970405500206","article-title":"Calcium dobesilate for chronic venous insufficiency: a systematic review","volume":"55","author":"Ciapponi","year":"2004","journal-title":"Angiology"},{"key":"10.1016\/j.jvsv.2025.102258_bib38","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ejvs.2007.08.012","article-title":"A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease","volume":"35","author":"Martinez-Zapata","year":"2008","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jvsv.2025.102258_bib39","doi-asserted-by":"crossref","first-page":"143","DOI":"10.23736\/S0392-9590.18.03975-5","article-title":"Efficacy of micronized purified flavonoid fraction (Daflon(R)) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials","volume":"37","author":"Kakkos","year":"2018","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2025.102258_bib40","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1007\/s12325-023-02643-6","article-title":"Vein STEP: a prospective, observational, international study to assess effectiveness of conservative treatments in chronic venous disease","volume":"40","author":"Mezalek","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.jvsv.2025.102258_bib41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/jps.1168","article-title":"Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry and liquid scintillation counting","volume":"91","author":"Garner","year":"2002","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jvsv.2025.102258_bib42","first-page":"109","article-title":"Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I-II). A randomized, double-blind, placebo-controlled trial","volume":"50","author":"Kiesewetter","year":"2000","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.jvsv.2025.102258_bib43","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/0003319707305407","article-title":"Randomized, double blind, placebo-controlled clinical trial to evaluate the lymphagogue effect and clinical efficacy of calcium dobesilate in chronic venous disease","volume":"59","author":"Flota-Cervera","year":"2008","journal-title":"Angiology"},{"key":"10.1016\/j.jvsv.2025.102258_bib44","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1258\/phleb.2010.010051","article-title":"Calcium dobesilate in patients suffering from chronic venous insufficiency: a double-blind, placebo-controlled, clinical trial","volume":"26","author":"Rabe","year":"2011","journal-title":"Phlebology"},{"key":"10.1016\/j.jvsv.2025.102258_bib45","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/0268355515586097","article-title":"A randomized, double-blind, placebo-controlled, clinical study on the efficacy and safety of calcium dobesilate in the treatment of chronic venous insufficiency","volume":"31","author":"Rabe","year":"2016","journal-title":"Phlebology"},{"key":"10.1016\/j.jvsv.2025.102258_bib46","series-title":"Statistical Power analysis in the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.jvsv.2025.102258_bib47","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2147\/VHRM.S324112","article-title":"Is there a difference in the clinical efficacy of diosmin and micronized purified flavonoid fraction for the treatment of chronic venous disorders? Review of available evidence","volume":"17","author":"Cazaubon","year":"2021","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jvsv.2025.102258_bib48","first-page":"310","article-title":"Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema","volume":"31","author":"Allaert","year":"2012","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2025.102258_bib49","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(96)90467-5","article-title":"Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency","volume":"347","author":"Diehm","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jvsv.2025.102258_bib50","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/0268355513489550","article-title":"Veno-active drugs for chronic venous disease: a randomized, double-blind, placebo-controlled parallel-design trial","volume":"29","author":"Belczak","year":"2014","journal-title":"Phlebology"},{"key":"10.1016\/j.jvsv.2025.102258_bib51","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1002\/ptr.6705","article-title":"Red vine leaf extract (AS 195) can improve some signs and symptoms of chronic venous insufficiency, a systematic review","volume":"34","author":"Azhdari","year":"2020","journal-title":"Phytother Res"},{"key":"10.1016\/j.jvsv.2025.102258_bib52","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/00126839-200405020-00001","article-title":"Improvement of cutaneous microcirculation and oxygen supply in patients with chronic venous insufficiency by orally administered extract of red vine leaves AS 195: a randomised, double-blind, placebo-controlled, crossover study","volume":"5","author":"Kalus","year":"2004","journal-title":"Drugs R D"},{"key":"10.1016\/j.jvsv.2025.102258_bib53","first-page":"250","article-title":"Meta-analysis of clinical trials of Cyclo 3 Fort in the treatment of chronic venous insufficiency","volume":"22","author":"Boyle","year":"2003","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2025.102258_bib54","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ejvs.2005.04.017","article-title":"Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction","volume":"30","author":"Coleridge-Smith","year":"2005","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jvsv.2025.102258_bib55","first-page":"CD006477","article-title":"Flavonoids for treating venous leg ulcers","volume":"2013","author":"Scallon","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jvsv.2025.102258_bib56","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1055\/s-0037-1613116","article-title":"Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers","volume":"87","author":"Coccheri","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jvsv.2025.102258_bib57","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-0037-1621458","article-title":"Treatment of venous leg ulcers with sulodexide","volume":"32","author":"Kucharzewski","year":"2003","journal-title":"Phlebologie"},{"key":"10.1016\/j.jvsv.2025.102258_bib58","first-page":"CD010694","article-title":"Sulodexide for treating venous leg ulcers","volume":"2016","author":"Wu","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jvsv.2025.102258_bib59","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/0268355515619562","article-title":"Pharmacological adjuncts for chronic venous ulcer healing","volume":"31","author":"Coccheri","year":"2016","journal-title":"Phlebology"},{"key":"10.1016\/j.jvsv.2025.102258_bib60","first-page":"82","article-title":"Sulodexide and phlebotonics in the treatment of venous ulcer","volume":"36","author":"Gonzalez","year":"2017","journal-title":"Int Angiol"},{"issue":"Suppl 1.1","key":"10.1016\/j.jvsv.2025.102258_bib61","first-page":"29","article-title":"Two multi-centre clinical trials of two different dosages of O-(B-Hydroxyethyl)-Rutosides treatment of leg ulcers","volume":"8","author":"Schultz-Ehrenburg","year":"1993","journal-title":"Phlebology"},{"key":"10.1016\/j.jvsv.2025.102258_bib62","first-page":"617","article-title":"Therapeutic benefit of hydroxyethylrutosides (HR) in venous ulcer treatment. A controlled multicentre study","volume":"1","author":"Stegmann","year":"1986","journal-title":"Phlebology"},{"key":"10.1016\/j.jvsv.2025.102258_bib63","first-page":"53","article-title":"Treatment of venous ulcers with troxerutin: a randomised double-blind, controlled study","volume":"15","author":"Zuccarelli","year":"1996","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2025.102258_bib64","first-page":"254","article-title":"Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor","volume":"112","author":"Hammerschmidt","year":"1988","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.jvsv.2025.102258_bib65","first-page":"CD001733","article-title":"Pentoxifylline for treating venous leg ulcers","volume":"12","author":"Jull","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jvsv.2025.102258_bib66","first-page":"S1","article-title":"Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg","volume":"7","author":"Laurent","year":"1988","journal-title":"Int Angiol"},{"key":"10.1016\/j.jvsv.2025.102258_bib67","first-page":"376","article-title":"L\u2019insuffisance veineuse et Daflon 500 mg","volume":"9","author":"Planchon","year":"1990","journal-title":"Arteres et Veines"},{"key":"10.1016\/j.jvsv.2025.102258_bib68","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1177\/0268355516686451","article-title":"Functional chronic venous disease: a systematic review","volume":"32","author":"Serra","year":"2017","journal-title":"Phlebology"}],"container-title":["Journal of Vascular Surgery: Venous and Lymphatic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213333X25000939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213333X25000939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T01:15:06Z","timestamp":1754529306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213333X25000939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2213333X25000939"],"URL":"https:\/\/doi.org\/10.1016\/j.jvsv.2025.102258","relation":{},"ISSN":["2213-333X"],"issn-type":[{"value":"2213-333X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of venoactive compounds in the treatment of chronic venous disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular Surgery: Venous and Lymphatic Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvsv.2025.102258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the Society for Vascular Surgery.","name":"copyright","label":"Copyright"}],"article-number":"102258"}}